0 147

Cited 0 times in

A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors

DC Field Value Language
dc.date.accessioned2023-06-02T00:37:24Z-
dc.date.available2023-06-02T00:37:24Z-
dc.date.issued2022-03-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194314-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleA first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorT. Yun-
dc.contributor.googleauthorS.J. Shin-
dc.contributor.googleauthorD-W. Kim-
dc.contributor.googleauthorC.H. Yun-
dc.contributor.googleauthorS. Heo-
dc.contributor.googleauthorB. Hyun-
dc.contributor.googleauthorY.S. Kim-
dc.contributor.googleauthorJ.S. Kim-
dc.contributor.googleauthorY.W. Moon-
dc.identifier.doi10.1016/j.annonc.2022.01.053-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S092375342200062X-
dc.citation.volume33-
dc.citation.numberSuppl.1-
dc.citation.startPageS20-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.33(Suppl.1) : S20, 2022-03-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.